@entity7274 in combination with 1-day versus 3-day @entity619 to prevent XXXX in @entity1 receiving @entity1311 and @entity3003 .

@entity1 @entity137 @entity9170 @entity5 @entity3003 @entity1311 @entity1209 @entity619 @entity40108 @entity7274 @entity1142 @entity15409 @entity22
PURPOSE: The aim of the present study was to evaluate the efficacy and @entity137 of @entity7274 ( @entity15409 ) and @entity619 ( @entity9170 ) on day 1 only in @entity1 with @entity5 receiving @entity1311 combined with @entity3003 ( @entity40108 ). The primary endpoint was to evaluate the complete response (CR) rate in the delayed phase. METHODS: This study was a randomized phase 2. Regardless of assignment to either study arm, all @entity1 received an intravenous prophylactic regimen of @entity9170 (20  mg) within 15  min and then an intravenous dose of @entity15409 (0.75  mg) as a bolus given 30  min before initiation of @entity40108 on day 1. @entity1 in the @entity9170 1-day group received no additional @entity9170 on days 2 and 3. @entity1 in the @entity9170 3-day group received @entity9170 (8  mg) orally on days 2 and 3. RESULTS: Eighty-two @entity1 had evaluable data on the primary outcome. The CR rates in the delayed phase between the two groups were not statistically significantly different (3-day group, 76.9  % [30/39]; 1-day group 69.8  % [30/43]; p   =   0.4652). The frequency of @entity1142 and @entity22 which were antiemetic treatment-related adverse events was similar between two groups, and no serious adverse events occurred. CONCLUSIONS: Administration of a combination of @entity15409 and @entity9170 1  day may prevent chemotherapy-induced @entity1209 (CINV) in the delayed phase for @entity40108 as well as administration of @entity9170 3  days. Further evaluation of the antiemetic regimen of combination of @entity15409 and @entity9170 1  day for @entity40108 is warranted in future phase 3 trials.
